Navigation Links
Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)

NEW YORK, March 20 /PRNewswire/ -- Dreier LLP ( announces that a class action lawsuit was commenced in the U.S. District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (Nasdaq: VRTX) publicly traded securities during the period from June 12, 2007 through November 2, 2007, inclusive (the "Class Period"). The Complaint alleges that Vertex and certain of the Company's officers and directors (collectively, the "Defendants") violated the Securities Exchange Act of 1934.

If you purchased Vertex publicly traded securities during the Class Period, you may be a member of the proposed Class. You must move the Court on or before May 12, 2008 if you wish to serve as a lead plaintiff. Lead plaintiffs must meet certain legal requirements. If you purchased Vertex publicly traded securities and want to discuss your legal rights, you may contact Bruce D. Bernstein ( of Dreier LLP at 800-952- 8897. Class members may retain counsel of their choice and move the Court to serve as a lead plaintiff, or may choose to do nothing and remain absent class members.

Vertex is a pharmaceutical company engaged in the discovery, development and commercialization of small molecule drugs for the treatment of serious diseases.

The Complaint alleges that, among other things, during the Class Period Defendants misled investors by making materially false and misleading statements concerning the development of Vertex's new HCV protease inhibitor: telaprevir or VX-950. Ultimately, Vertex intends to use the inhibitor in a new drug targeted at the treatment of hepatitis C. Among other things, the Complaint alleges that Defendants made positive statements concerning VX-950 and the Company's PROVE 2 trial while simultaneously failing to disclose unfavorable data uncovered during the PROVE 2 trial. On November 2, 2007, before the market closed, the Company disclosed the truth concerning the PROVE 2 trial. As a direct and proximate result of this news, the price of Vertex stock declined $2.74 per share to close at $28.90 per share, a one day decline of 9%, on extremely high trading volume.

Dreier LLP's Class Action Litigation Group has vast experience representing domestic and foreign institutional and individual investors in securities and other class actions throughout the country. The partners who head Dreier LLP's Class Action Litigation Group have successfully prosecuted securities fraud class actions in a wide variety of industries and have played a significant role in cases that have resulted in some of the largest securities class action settlements. Prior results do not guarantee a similar outcome. As of the date of this Notice, Dreier LLP has not filed a Complaint against Vertex.

Background on Dreier LLP

Dreier LLP was founded in 1996 by Marc Dreier as a more responsive and innovative alternative to traditional "large-firm" lawyering. Dreier LLP represents a wide range of institutional, entrepreneurial and individual clients in diverse sectors of financial, industrial and service-oriented markets. The firm's principal practices are commercial litigation, class action litigation, real estate, bankruptcy and corporate reorganization, employment, corporate and securities, entertainment, intellectual property, matrimonial and tax. Dreier LLP's Los Angeles affiliate, Dreier Stein Kahan Browne Woods George LLP, has its principal practice in entertainment and commercial litigation and corporate transactions. The firm's New York affiliate Schlesinger Gannon & Lazetera LLP has an extensive practice in the area of trusts and estates law. Pitta & Dreier LLP is an affiliate which specializes in labor law, and Pitta, Bishop, Del Giorno & Dreier LLP specializes in government relations. In the 12 years since its founding, Dreier LLP, with its affiliate members, has grown to more than 200 attorneys, with its principal office at 499 Park Avenue in Manhattan, and additional offices in Los Angeles and Santa Monica, California; Albany, New York; and Stamford, Connecticut.

Attorney advertising

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Blue Cross and Blue Shield of Illinois Announces Wellness Tools and Resources
2. Blue Cross and Blue Shield of Illinois Announces Campaign to Address Childhood Obesity
3. Blue Cross and Blue Shield of Illinois Announces 2007 Charitable Donations
4. IPC The Hospitalist Company Announces Board of Director Member Changes
5. MedCom Announces Court Rules Card Activation Technologies Patent Is Valid
6. Patrick G. Ryan Announces Intention to Retire from Aon
7. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
8. Takeda Announces New U.S. Leadership
9. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
10. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
11. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
Post Your Comments:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology: